Welcome to our dedicated page for Pmv Pharmaceuticals SEC filings (Ticker: PMVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PMV Pharmaceuticals filings document a clinical-stage precision oncology company focused on small molecule therapies targeting p53. The company’s Form 8-K reports disclose operating results, financial condition updates, Regulation FD materials, and rezatapopt clinical disclosures from the PYNNACLE study in tumors with a TP53 Y220C mutation.
Proxy materials describe annual meeting matters, board composition, stockholder voting procedures, and governance practices. The filing record also identifies PMV’s Nasdaq-listed common stock and includes risk and forward-looking-statement disclosures tied to drug development, regulatory pathways, capital resources, and clinical-stage biotechnology operations.
PMV Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on June 4, 2026 at 10:00 a.m. Eastern. Investors will elect two Class III directors, David H. Mack, Ph.D. and Laurie Stelzer, approve on a non-binding basis executive pay, and ratify Ernst & Young LLP as auditor for 2026.
The company will reduce its board from seven to six members as chair Richard Heyman, Ph.D. departs, and plans for director Laurie Stelzer to become board chair while David Mack remains CEO. The proxy describes Nasdaq independence compliance, committee structures, ESG oversight and detailed director compensation.
The filing also reviews 2025 executive pay, including total 2025 compensation of $1.7 million for CEO David Mack, and explains the prior 2025 say-on-pay failure, linking stockholder concerns mainly to a 2024 employee-only option exchange the board views as a one-time event.
PMV Pharmaceuticals, Inc. Chief Financial Officer Michael Carulli reported an equity compensation grant and updated his share holdings. He received an employee stock option for 240,000 shares of common stock at an exercise price of $0.00 per share, classified as a grant or award acquisition.
The option vests in 48 equal monthly installments beginning on April 5, 2026, which means the award vests gradually over four years. Following this filing, Carulli directly holds 73,848 shares of common stock, which includes 13,702 shares acquired under the company’s Employee Stock Purchase Plan on November 20, 2025.
PMV Pharmaceuticals reported that its General Counsel & COO, Robert Ticktin, received a grant of 319,270 employee stock options. These options give him the right to buy PMV Pharmaceuticals stock in the future, rather than representing shares bought on the open market.
The options were granted at an exercise price listed as $0.0000 per share in the filing and will vest over time. According to the footnote, the award vests in 48 equal monthly installments beginning on April 3, 2026, meaning the executive gains the right to exercise portions of the grant gradually over four years.
PMV Pharmaceuticals, Inc. reported that Chief Development Officer Deepika Jalota received an employee stock option grant. The award covers 303,310 options to purchase company stock and is classified as a grant or award acquisition. According to the terms, these options begin vesting on April 5, 2026, in 48 equal monthly installments, meaning the award vests gradually over four years, which is designed to align the executive’s incentives with the company’s longer-term performance.
PMV Pharmaceuticals, Inc. granted President and CEO David Henry Mack an employee stock option covering 744,960 shares of common stock. The award was reported as an acquisition of derivative securities at a stated price of 0.0000 per share. These options vest in 48 equal monthly installments beginning on April 5, 2026, providing long-term, time-based equity compensation tied to his continued service.
PMV Pharmaceuticals, Inc. reported full-year 2025 results and highlighted progress for its lead p53 reactivator, rezatapopt. The Phase 2 PYNNACLE trial showed a 34% overall response rate among 103 evaluable patients and a 46% response rate in 48 ovarian cancer patients, with responses lasting around 8 months.
Rezatapopt received U.S. FDA Orphan Drug Designation for TP53 Y220C–positive ovarian, fallopian tube, and primary peritoneal cancers, and Phase 1 data were published in the New England Journal of Medicine. As of December 31, 2025, PMV held $112.9 million in cash, cash equivalents, and marketable securities, providing expected cash runway to the end of the second quarter of 2027.
Net loss for 2025 was $77.7 million versus $58.7 million in 2024, driven mainly by higher research and development spending of $69.9 million. General and administrative expenses decreased to $16.3 million from $26.9 million, reflecting lower facility and personnel costs after prior-year restructuring.
PMV Pharmaceuticals is a precision oncology company developing small-molecule, tumor-agnostic therapies targeting mutant p53, led by rezatapopt for the p53 Y220C mutation. In the Phase 2 pivotal PYNNACLE trial, rezatapopt achieved a 34% overall response rate in 103 efficacy-evaluable patients and a 46% response rate in 48 ovarian cancer patients, with median response durations of 7.6 and 8.0 months. Rezatapopt has FDA Fast Track and orphan drug designations, and the company plans to submit a New Drug Application for platinum-resistant or refractory TP53 Y220C ovarian cancer in the first quarter of 2027. PMV is also advancing additional p53-focused programs, building companion diagnostics with FoundationOne CDx, and preparing commercialization infrastructure and IP protection around its platform.
PMV Pharmaceuticals’ large shareholder OrbiMed exits its position. OrbiMed Advisors LLC and OrbiMed Capital GP V LLC report that, as of March 2, 2026, they beneficially own 0 shares of PMV common stock, representing 0% of the 53,211,507 shares outstanding.
The exit follows sales by OrbiMed Private Investments V, LP of 505,000 shares on February 27, 2026 and 4,470,291 shares on March 2, 2026, each at a price of $1.62 per share. This amendment is characterized as an exit filing because their ownership fell by more than 1% and below the 5% reporting threshold.
ArrowMark Colorado Holdings, LLC filed an amended beneficial ownership report on PMV Pharmaceuticals, Inc. common stock. The firm reports beneficial ownership of 3,090,093 shares, representing 5.81% of the outstanding common stock as of the event date.
ArrowMark states it has sole voting and dispositive power over all reported shares and no shared power. The filing also certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PMV Pharmaceuticals.